PD-L1
Assets acting on this target.
- Class
- anti-PD-L1 monoclonal antibody
- Pathway
- PD-1/PD-L1 immune checkpoint blockade
PD-L1 (programmed death-ligand 1) is a cell-surface protein expressed on tumor cells and on various normal and immune cells. It binds the receptor PD-1 on activated T lymphocytes, delivering an inhibitory signal that dampens T-cell activity. This interaction is part of a normal feedback system that limits immune responses and protects healthy tissue from collateral damage during inflammation. Many tumors exploit this pathway by upregulating PD-L1, effectively disguising themselves from immune attack by engaging PD-1 on tumor-infiltrating T cells. Agents that block PD-L1 (or its partner PD-1) interrupt this inhibitory signal, releasing a brake on T-cell function and allowing the immune system to recognize and attack cancer cells more effectively. This general strategy, known as immune checkpoint blockade, has broad relevance across many solid tumor types where immune evasion via this axis contributes to disease progression. Because the pathway is a normal regulator of immune tolerance, blocking it can also unleash immune activity against healthy tissue, producing inflammatory side effects. PD-L1-directed antibodies are one of two principal ways to interrupt this axis, the other being direct blockade of the PD-1 receptor itself, and various modalities including antibody-drug conjugates have been explored to combine checkpoint blockade with direct tumor cell targeting.
By indication
PD-L1 drugs compared
13 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Atezolizumab | Chugai Pharma, Roche | monoclonal antibody | Approved | Approved in Bladder Cancer; Approved in Colorectal Cancer; Approved in Hepatocellular Carcinoma; Approved in Melanoma; Approved in Non-Small Cell Lung Cancer; Approved in Small Cell Lung Cancer |
| Avelumab | Merck KGaA | monoclonal antibody | Approved | Approved in Merkel Cell Carcinoma; Approved in Renal Cell Carcinoma; Approved in Urothelial Carcinoma |
| Durvalumab | AstraZeneca | monoclonal antibody | Approved | Approved in Biliary Tract Cancer; Approved in Bladder Cancer; Approved in Endometrial Cancer; Approved in Hepatocellular Carcinoma; Approved in Non-Muscle Invasive Bladder Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Small Cell Lung Cancer; Phase 3 in Ovarian Cancer; Phase 3 in Renal Cell Carcinoma; Phase 3 in Urothelial Carcinoma |
| Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) | Roche | monoclonal antibody | Approved | Approved in Bladder Cancer; Approved in Hepatocellular Carcinoma; Approved in Melanoma; Approved in Non-Small Cell Lung Cancer; Approved in Small Cell Lung Cancer |
| Adebrelimab | Jiangsu Hengrui Pharmaceuticals | monoclonal antibody | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Small Cell Lung Cancer |
| Envafolimab | 3D Medicines Inc., Ascletis Pharma, Glenmark Pharmaceuticals Ltd., Simcere Pharmaceutical, Suzhou Alphamab | monoclonal antibody | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer; Phase 2 in Chronic Hepatitis B; Phase 2 in Endometrial Cancer; Phase 2 in HIV |
| Fetrastobart vedotin | Pfizer, Seagen | antibody-drug conjugate | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| SugemalimabCejemly | CStone Pharmaceuticals, Ewopharma, Istituto Gentili S.R.L., Laboratorios Stein S.A., Pfizer | monoclonal antibody | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Tagitanlimab | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | monoclonal antibody | Phase 3 | Phase 3 in Nasopharyngeal Carcinoma; Phase 2 in HR+/HER2- Metastatic Breast Cancer; Phase 2 in Non-Small Cell Lung Cancer |
| HLX43 | Shanghai Henlius Biotech | antibody-drug conjugate | Phase 2/3 | Phase 2/3 in Non-Small Cell Lung Cancer; Phase 2 in HR+/HER2- Metastatic Breast Cancer |
| 177Lu-RAD204 | Radiopharm Theranostics, Ltd | radiopharmaceutical | Phase 1 | Phase 1 in Non-Small Cell Lung Cancer |
| BPI-371153 | Betta Pharmaceuticals Co. | small molecule | Phase 1 | Phase 1 in Non-Small Cell Lung Cancer |
| IBC-Ab002 | Immunobrain Checkpoint | monoclonal antibody | Phase 1 | Phase 1 in Alzheimer's Disease |